Diskussionsleiter: C. Birner (Amberg), A. A. Derda (Hannover)
| (P189) | Impact of phosphodiesterase-5 Inhibitors on right ventricular function and exercise capacity after left ventricular assist-device implantation: the PIVAD study | |
| A. M. Jakstaite, M. Papathanasiou, N. Pizanis, B. Schmack, M. Kamler, A. Ruhparwar, T. Rassaf, P. Lüdike (Essen) | ||
| (P190) | Sex differences in clinical characteristics and outcomes in advanced heart failure patients referred to a specialized outpatient clinic | |
| N. Fluschnik, F. Strangl, C. Kondziella, A. Goßling, P. M. Becher, W. Bremer, J. Bernadyn, R. Schnabel, M. Rybczynski, S. Blankenberg, B. Schrage, P. Kirchhof, C. Magnussen, D. Knappe (Hamburg) | ||
| (P191) | Association between NT-proBNP and one-year outcome among systemic amyloidosis patients with renal, cardiac, or combined cardiac and renal involvement | |
| B. D. Lengenfelder, S. Frantz (Würzburg) | ||
| (P192) | Impact of amyloidosis on outcomes of patients with heart failure | |
| S. Göbel, L. Hobohm, T. Gori, T. Münzel, P. Wenzel, K. Keller (Mainz) | ||
| (P193) | Non-invasive risk prediction based on RV function in patients with pulmonary arterial hypertension | |
| V. Qaderi, L. Harbaum, J. Weimann, B. Schrage, C. Sinning, R. Schnabel, S. Blankenberg, P. Kirchhof, H. Klose, C. Magnussen (Hamburg) | ||
| (P194) | Immune-metabolome response to a single exercise exertion reveals dysfunctional metabolic recovery in heart failure | |
| M. Bahls, N. Kränkel, A. Koc, S. Kaczmarek, K. Lehnert, I. Urbaneck, U. Landmesser, S. B. Felix, M. Dörr (Greifswald, Berlin) | ||
| (P195) | Copeptin is Associated with Pronounced Stages of Heart Failure with Preserved Ejection Fraction | |
| M. Natale, M. Harbrücker, U. Ansari, T. Bertsch, T. Roth, S. Lindner, S.-H. Kim, J. Müller, M. Borggrefe, S. Lang, U. Hoffmann, I. Akin, M. Behnes (Mannheim, Nürnberg, Erlangen) | ||
| (P196) | MR-proADM is Associated with Advanced Grades of Heart Failure with Preserved Ejection Fraction | |
| M. Natale, M. Harbrücker, U. Ansari, T. Bertsch, T. Roth, S. Lindner, S.-H. Kim, J. Müller, M. Borggrefe, S. Lang, U. Hoffmann, I. Akin, M. Behnes (Mannheim, Nürnberg, Erlangen) | ||
| (P197) | Identification of Three Clinical Phenotypes of Cardiogenic Shock | |
| E. Zweck, K. L. Thayer, O. K. L. Helgestad, M. Kanwar, M. Ayouty, A. R. Garan, J. Hernandez-Montfort, C. Mahr, D. Wencker, S. Sinha, E. Vorovich, W. O'Neill, J. Abraham, G. W. Hickey, J. Josiassen, C. Hassager, L. O. Jensen, L. Holmvang, H. Schmidt, H. B. Ravn, J. Moeller, D. Burkhoff, N. Kapur (Boston; Boston, Pittsburgh, Weston, Seattle, Dallas, Falls Church, Chicago, Detroit, Portland, New York, US; Odense, Kopenhagen, DK) | ||
| (P198) | NAG: potential cardiorenal biomarker indicates progression of chronic kidney disease in ICD patients | |
| R. Allgaier, C. Strack, S. Wallner, U. Hubauer, E. Ücer, P. Lehn, A. Keyser, A. Luchner, L. S. Maier, C. G. Jungbauer (Regensburg) | ||
| (P199) | Optimale Antikoagulationsstrategie bei Patienten im kardiogenen Schock mit mechanischer Impella™ Unterstützung | |
| R. M'Pembele, C. Vandenbriele, L. K. Dannenberg, S. Zako, D. Metzen, P. Mourikis, K. Trojovsky, D. Ignatov, R. Huhn-Wientgen, C. Jung, P. Horn, T. Zeus, R. Westenfeld, M. Kelm, A. Polzin (Düsseldorf; Leuven, BE) | ||
| (P200) | Seasonal Trends of Incidence and Outcomes of Cardiogenic Shock: Findings from a Large, Nationwide Inpatients Sample with 441,696 Cases | |
| P. M. Becher, B. Schrage, A. Goßling, M. Seiffert, P. Kirchhof, S. Blankenberg, D. Westermann (Hamburg) |
